Cargando…

Sugammadex and anaphylaxis: An analysis of 33 published cases

In this study, the published sugammadex-induced anaphylaxis reports were reviewed to determine similarities in their presentation during anesthesia. PubMed was searched for sugammadex-induced anaphylaxis without time limitation. Reports were evaluated if they were in English and met the criteria of...

Descripción completa

Detalles Bibliográficos
Autores principales: Arslan, Baris, Sahin, Tuna, Ozdogan, Hatice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8289668/
https://www.ncbi.nlm.nih.gov/pubmed/34349361
http://dx.doi.org/10.4103/joacp.JOACP_383_19
_version_ 1783724338747277312
author Arslan, Baris
Sahin, Tuna
Ozdogan, Hatice
author_facet Arslan, Baris
Sahin, Tuna
Ozdogan, Hatice
author_sort Arslan, Baris
collection PubMed
description In this study, the published sugammadex-induced anaphylaxis reports were reviewed to determine similarities in their presentation during anesthesia. PubMed was searched for sugammadex-induced anaphylaxis without time limitation. Reports were evaluated if they were in English and met the criteria of anaphylaxis determined by the World Allergy Organization. Two independent reviewers extracted and assessed the data using predesigned data collection forms. In total, 23 suitable articles were found and 33 sugammadex-induced anaphylaxis cases were included in the study. The mean age was 43.09 years (from 3–89 years) and 17 (51.5%) of the patients were female. Considering all reported cases, the average onset time of anaphylaxis was 3.08 min, with a median of 3 min (range 1–8 min). The most common signs and symptoms were hypotension, tachycardia, erythema, and desaturation. Of the 20 patients who underwent confirmatory skin testing, 15 had a positive skin reaction for sugammadex. Epinephrine was not given when indicated in about 25% of cases. Sugammadex-induced anaphylaxis onset time was less than 5 min in 92.3% of all the reported cases. Rapid diagnosis and early recognition of signs and symptoms of anaphylaxis are essential for a favorable prognosis. Treatment needs to be started as soon as possible to ensure the best outcome for the patient.
format Online
Article
Text
id pubmed-8289668
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-82896682021-08-03 Sugammadex and anaphylaxis: An analysis of 33 published cases Arslan, Baris Sahin, Tuna Ozdogan, Hatice J Anaesthesiol Clin Pharmacol Review Article In this study, the published sugammadex-induced anaphylaxis reports were reviewed to determine similarities in their presentation during anesthesia. PubMed was searched for sugammadex-induced anaphylaxis without time limitation. Reports were evaluated if they were in English and met the criteria of anaphylaxis determined by the World Allergy Organization. Two independent reviewers extracted and assessed the data using predesigned data collection forms. In total, 23 suitable articles were found and 33 sugammadex-induced anaphylaxis cases were included in the study. The mean age was 43.09 years (from 3–89 years) and 17 (51.5%) of the patients were female. Considering all reported cases, the average onset time of anaphylaxis was 3.08 min, with a median of 3 min (range 1–8 min). The most common signs and symptoms were hypotension, tachycardia, erythema, and desaturation. Of the 20 patients who underwent confirmatory skin testing, 15 had a positive skin reaction for sugammadex. Epinephrine was not given when indicated in about 25% of cases. Sugammadex-induced anaphylaxis onset time was less than 5 min in 92.3% of all the reported cases. Rapid diagnosis and early recognition of signs and symptoms of anaphylaxis are essential for a favorable prognosis. Treatment needs to be started as soon as possible to ensure the best outcome for the patient. Wolters Kluwer - Medknow 2021 2021-07-15 /pmc/articles/PMC8289668/ /pubmed/34349361 http://dx.doi.org/10.4103/joacp.JOACP_383_19 Text en Copyright: © 2021 Journal of Anaesthesiology Clinical Pharmacology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review Article
Arslan, Baris
Sahin, Tuna
Ozdogan, Hatice
Sugammadex and anaphylaxis: An analysis of 33 published cases
title Sugammadex and anaphylaxis: An analysis of 33 published cases
title_full Sugammadex and anaphylaxis: An analysis of 33 published cases
title_fullStr Sugammadex and anaphylaxis: An analysis of 33 published cases
title_full_unstemmed Sugammadex and anaphylaxis: An analysis of 33 published cases
title_short Sugammadex and anaphylaxis: An analysis of 33 published cases
title_sort sugammadex and anaphylaxis: an analysis of 33 published cases
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8289668/
https://www.ncbi.nlm.nih.gov/pubmed/34349361
http://dx.doi.org/10.4103/joacp.JOACP_383_19
work_keys_str_mv AT arslanbaris sugammadexandanaphylaxisananalysisof33publishedcases
AT sahintuna sugammadexandanaphylaxisananalysisof33publishedcases
AT ozdoganhatice sugammadexandanaphylaxisananalysisof33publishedcases